Donate

Industry News

The following is an excerpt from an update from Takeda. Read the update in its entirety here.


Takeda recently informed HFA of it’s decision to suspend screening and further enrollment in the TAK-754 and TAK-748 clinical studies, effective immediately.

TAK-754 is an AAV8 gene therapy for the treatment of hemophilia A currently in Phase 1/2 clinical development, while TAK-748 is an AAV8 gene therapy for the treatment of hemophilia B in Phase 1/2 study start-up (no subject dosed as of today). In order to determine the most appropriate way forward for both TAK-754 and TAK-748, Takeda is currently assessing the interim data from the ongoing Phase 1/2 study of TAK-754 in hemophilia A, together with the overall current gene therapy landscape in hemophilia. Takeda will communicate more details on these results to the community in due time once their assessment has been finalized. Takeda notes that this decision is not a result of any safety concerns with TAK-754 and TAK-748.

Takeda has informed investigators who are working directly on these studies. Those who are enrolled will continue to be under close clinical observation according to study protocol, and those who were planned to be enrolled into these studies will be informed and transitioned smoothly.

Read the update in its entirety here.

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.